CAREY STEPHEN P. sold $240K of ANIP
CAREY STEPHEN P. (SVP & CFO) sold 2,850 shares of ANI PHARMACEUTICALS INC (ANIP) at $84.12 ($0.24M total) on 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s planned open-market sale of 2,850 shares at $84.12, with holdings after the transaction of 177,543 shares.
Market read
Insider selling can influence short-term sentiment, but the 10b5-1 designation makes this more of a routine flow than a new fundamental signal.
What to watch
The filing does not disclose any new operational, financial, or regulatory information—so traders should avoid over-weighting it versus upcoming company catalysts (earnings, guidance, trial updates).
Background
The article is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals, Inc. (ANIP).
Ticker impact
ANIP’s SVP & CFO Stephen P. Carey filed a Form 4 selling 2,850 shares at $84.12 on 2026-06-29 under a 10b5-1 plan.
Likely limited near-term impact; any reaction should be small and fade as it’s a planned sale.
The filing specifies code S (open-market sale) and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerANI Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderStephen P. Carey
SVP & CFO who sold shares (open-market sale) under a 10b5-1 plan.
- trading plan10b5-1 plan
Pre-arranged plan that typically reduces interpretive signal from insider selling.
